MCM
RARE icon

Moore Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Moore Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200,000
Closed -$7.27M – 715
2025
Q2 		$7.27M Buy
+200,000
New +$7.21M 0.09% 171

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Moore Capital Management's RARE Position: Q2 2026 in Review

Moore Capital Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 19% in Q2 2026, selling an estimated $723K and leaving 128,035 shares worth $4.28M. The position accounts for 0.06% of the portfolio, ranked #258.

Moore Capital Management first reported a position in RARE in Q1 2015 and has held it in 16 quarters since. The position peaked at $13.6M in Q3 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Moore Capital Management held 128,035 shares of Ultragenyx Pharmaceutical worth $4.28M as of Q2 2026.
  • Moore Capital Management sold 29,097 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $723K.
  • Ultragenyx Pharmaceutical made up 0.06% of Moore Capital Management's portfolio in Q2 2026, its #258 holding.
  • Moore Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 16 quarters since.
  • Moore Capital Management's Ultragenyx Pharmaceutical position peaked at $13.6M in Q3 2024.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.